- Home
- ONC
as 05-30-2025 4:00pm EST
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
| Founded: | 2010 | Country: | Switzerland |
| Employees: | N/A | City: | GRAND CAYMAN |
| Market Cap: | 26.9B | IPO Year: | N/A |
| Target Price: | $326.43 | AVG Volume (30 days): | 368.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $141.31 - $287.88 | Next Earning Date: | 05-07-2025 |
| Revenue: | $4,180,740,829 | Revenue Growth: | 52.09% |
| Revenue Growth (this year): | 32.78% | Revenue Growth (next year): | 19.07% |
Latest BeiGene Ltd. American Depositary Shares News
ONC Breaking Stock News: Dive into ONC Ticker-Specific Updates for Smart Investing
Business Wire
13 hours ago
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
MT Newswires
4 days ago
Sector Update: Health Care Stocks Rise Premarket Tuesday
MT Newswires
4 days ago
Sector Update: Health Care
Business Wire
5 days ago
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
MT Newswires
5 days ago
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
Business Wire
5 days ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
Simply Wall St.
10 days ago
Exploring US High Growth Tech Stocks In May 2025
Business Wire
10 days ago
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
Compare ONC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONC BeiGene Ltd. American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.